Symmetrical bis-tertiary amines as novel CXCR4 inhibitors

被引:19
作者
Bai, Renren [1 ]
Liang, Zhongxing [1 ,2 ]
Yoon, Younghyoun [1 ]
Liu, Shuangping [3 ]
Gaines, Theresa [4 ]
Oum, Yoonhyeun [1 ]
Shi, Qi [5 ]
Mooring, Suazette Reid [4 ]
Shim, Hyunsuk [1 ,2 ]
机构
[1] Emory Univ, Sch Med, Dept Radiol & Imaging Sci, 1365C Clifton Rd NE,C5008, Atlanta, GA 30322 USA
[2] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA
[3] Emory Univ, Sch Med, Dept Hematol & Med Oncol, Atlanta, GA 30322 USA
[4] Georgia State Univ, Dept Chem, Atlanta, GA 30303 USA
[5] Emory Univ, Dept Chem, 1515 Pierce Dr, Atlanta, GA 30322 USA
关键词
Tertiary amines; CXCR4; inhibitors; Binding affinity; Matrigel invasion; Anti-inflammatory activity; SMALL-MOLECULE; BREAST-CANCER; ANTIINFLAMMATORY DRUGS; CHEMOKINE RECEPTORS; ANTAGONISTS; METASTASIS; DISCOVERY; MIGRATION; CYCLOOXYGENASE-2; THERAPEUTICS;
D O I
10.1016/j.ejmech.2016.04.040
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
CXCR4 inhibitors are promising agents for the treatment of cancer metastasis and inflammation. A series of novel tertiary amine derivatives targeting CXCR4 were designed, synthesized, and evaluated. The central benzene ring linker and side chains were modified and optimized to study the structure-activity relationship. Seven compounds displayed much more potent activity than the reference drug, AMD3100, in both the binding affinity assay and the blocking of Matrigel invasion functional assay. These compounds exhibited effective concentration ranging from 1 to 100 nM in the binding affinity assay and inhibited invasion from 65.3% to 100% compared to AMD3100 at 100 nM. Compound fin showed a 50% suppressive effect against carrageenan-induced paw inflammation in a mouse model, which was as effective as the peptidic antagonist, TN14003 (48%). These data demonstrate that symmetrical bistertiary amines are unique CXCR4 inhibitors with high potency. (C) 2016 Elsevier Masson SAS. All rights reserved.
引用
收藏
页码:340 / 350
页数:11
相关论文
共 46 条
  • [1] Current status of chemokine receptor inhibitors in development
    Allegretti, Marcello
    Cesta, Maria Candida
    Garin, Alexandre
    Proudfoot, Amanda E. I.
    [J]. IMMUNOLOGY LETTERS, 2012, 145 (1-2) : 68 - 78
  • [2] [Anonymous], 2015, LIGPR VERS 3 6
  • [3] [Anonymous], SCHROD REL 2015 4 MA
  • [4] [Anonymous], GLID VERS 0 99
  • [5] [Anonymous], 2012, PROT PREP WIZ
  • [6] Cancer and the chemokine network
    Balkwill, F
    [J]. NATURE REVIEWS CANCER, 2004, 4 (07) : 540 - 550
  • [7] Stromal cell-derived factor 1 (CXCL12) induces human cell migration into human lymph nodes transplanted into SCID mice
    Blades, MC
    Manzo, A
    Ingegnoli, F
    Taylor, PR
    Panayi, GS
    Irjala, H
    Jalkanen, S
    Haskard, DO
    Perretti, M
    Pitzalis, C
    [J]. JOURNAL OF IMMUNOLOGY, 2002, 168 (09) : 4308 - 4317
  • [8] Small peptide inhibitors of the CXCR4 chemokine receptor (CD184) antagonize the activation, migration, and antiapoptotic responses of CXCL12 in chronic lymphocytic leukemia B cells
    Burger, M
    Hartmann, T
    Krome, M
    Rawluk, J
    Tamamura, H
    Fujii, N
    Kipps, TJ
    Burger, JA
    [J]. BLOOD, 2005, 106 (05) : 1824 - 1830
  • [9] Functional expression of CXCR4 (CD184) on small-cell lung cancer cells mediates migration, integrin activation, and adhesion to stromal cells
    Burger, M
    Glodek, A
    Hartmann, T
    Schmitt-Gräff, A
    Silberstein, LE
    Fujii, N
    Kipps, TJ
    Burger, JA
    [J]. ONCOGENE, 2003, 22 (50) : 8093 - 8101
  • [10] Drug Discovery Research Targeting the CXC Chemokine Receptor 4 (CXCR4)
    Choi, Won-Tak
    Duggineni, Srinivas
    Xu, Yan
    Huang, Ziwei
    An, Jing
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2012, 55 (03) : 977 - 994